Drug Trial Radar · NCT07511816
A Study of LY4515100 in Participants With Pain Following Third Molar Removal
Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
212
Planned (sponsor's estimate)
Start
Apr 1, 2026
Primary completion
Nov 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Apr 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of LY4515100 and see how a single oral dose compares with placebo in acute postsurgical pain after removing impacted third molars. For each participant, the study may last approximately 6 weeks and will include a stay in a Clinical Research Unit (CRU) after third molar removal.
Conditions
- Acute Pain
- Molar
- Molar, Third
- Surgery, Oral
Interventions
LY4515100Drug
Administered Orally
PlaceboDrug
Administered Orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Self-Reported Pain IntensityTime frame: Baseline, Up to Day 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
JBR Clinical Research
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.